A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Author:

Kim Chang Gon1ORCID,Hong Min Hee1ORCID,Kim Dahee2ORCID,Lee Brian Hyohyoung34ORCID,Kim Hyunwook1ORCID,Ock Chan-Young5ORCID,Kelly Geoffrey3ORCID,Bang Yoon Ji4ORCID,Kim Gamin1ORCID,Lee Jung Eun1ORCID,Kim Chaeyeon1ORCID,Kim Se-Heon2ORCID,Hong Hyun Jun2ORCID,Park Young Min2ORCID,Sim Nam Suk2ORCID,Park Heejung6ORCID,Park Jin Woo6ORCID,Lee Chang Geol7ORCID,Kim Kyung Hwan7ORCID,Park Goeun8ORCID,Jung Inkyung8ORCID,Han Dawoon9ORCID,Kim Jong Hoon9ORCID,Cha Junha10ORCID,Lee Insuk10ORCID,Kang Mingu5ORCID,Song Heon5ORCID,Oum Chiyoon5ORCID,Kim Seulki5ORCID,Kim Sukjun5ORCID,Lim Yoojoo5ORCID,Kim-Schulze Seunghee311ORCID,Merad Miriam31112ORCID,Yoon Sun Och6ORCID,Kim Hyun Je4131415ORCID,Koh Yoon Woo2ORCID,Kim Hye Ryun1ORCID

Affiliation:

1. 1Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.

2. 2Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea.

3. 3Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York.

4. 4Department of Biomedical Science, Seoul National University College of Medicine, Seoul, Republic of Korea.

5. 5Lunit Inc., Seoul, Republic of Korea.

6. 6Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea.

7. 7Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.

8. 8Division of Biostatistics, Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea.

9. 9Department of Dermatology and Cutaneous Biology Research Institute, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

10. 10Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea.

11. 11Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, New York.

12. 12Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

13. 13Genome Medicine Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.

14. 14Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.

15. 15Seoul National University Hospital, Seoul, Republic of Korea.

Abstract

Abstract Purpose: Clinical implications of neoadjuvant immunotherapy in patients with locally advanced but resectable head and neck squamous cell carcinoma (HNSCC) remain largely unexplored. Patients and Methods: Patients with resectable HNSCC were randomized to receive a single dose of preoperative durvalumab (D) with or without tremelimumab (T) before resection, followed by postoperative (chemo)radiotherapy based on multidisciplinary discretion and 1-year D treatment. Artificial intelligence (AI)–powered spatial distribution analysis of tumor-infiltrating lymphocytes and high-dimensional profiling of circulating immune cells tracked dynamic intratumoral and systemic immune responses. Results: Of the 48 patients enrolled (D, 24 patients; D+T, 24 patients), 45 underwent surgical resection per protocol (D, 21 patients; D+T, 24 patients). D±T had a favorable safety profile and did not delay surgery. Distant recurrence-free survival (DRFS) was significantly better in patients treated with D+T than in those treated with D monotherapy. AI-powered whole-slide image analysis demonstrated that D+T significantly reshaped the tumor microenvironment toward immune-inflamed phenotypes, in contrast with the D monotherapy or cytotoxic chemotherapy. High-dimensional profiling of circulating immune cells revealed a significant expansion of T-cell subsets characterized by proliferation and activation in response to D+T therapy, which was rare following D monotherapy. Importantly, expansion of specific clusters in CD8+ T cells and non-regulatory CD4+ T cells with activation and exhaustion programs was associated with prolonged DRFS in patients treated with D+T. Conclusions: Preoperative D±T is feasible and may benefit patients with resectable HNSCC. Distinct changes in the tumor microenvironment and circulating immune cells were induced by each treatment regimen, warranting further investigation.

Funder

Ministry of Science and ICT, South Korea

Ministry of Trade, Industry and Energy

Yonsei University College of Medicine

Yonsei University

Publisher

American Association for Cancer Research (AACR)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3